Royal Bank of Canada
GPCR icon

Royal Bank of Canada’s Structure Therapeutics GPCR Stock Holding History

Royal Bank of Canada’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35K Sell
722
-9,478
-93% -$649K ﹤0.01% 5656
2025
Q4 		$709K Sell
10,200
-93
-0.9% -$3.8K ﹤0.01% 3902
2025
Q3 		$288K Buy
10,293
+2,711
+36% +$54K ﹤0.01% 4853
2025
Q2 		$157K Buy
7,582
+3,871
+104% +$85.1K ﹤0.01% 5321
2025
Q1 		$64K Sell
3,711
-121,981
-97% -$2.99M ﹤0.01% 5455
2024
Q4 		$3.41M Buy
125,692
+8,147
+7% +$289K ﹤0.01% 2626
2024
Q3 		$5.16M Buy
117,545
+96,091
+448% +$3.72M ﹤0.01% 2254
2024
Q2 		$843K Sell
21,454
-38
-0.2% -$1.56K ﹤0.01% 3596
2024
Q1 		$921K Buy
21,492
+14,955
+229% +$631K ﹤0.01% 3532
2023
Q4 		$267K Buy
6,537
+6,434
+6,247% +$369K ﹤0.01% 4848
2023
Q3 		$5K Buy
+103
New +$3.32K ﹤0.01% 6607

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Royal Bank of Canada's GPCR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Structure Therapeutics (GPCR) stake by 93% in Q1 2026, selling an estimated $649K and leaving 722 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #5656.

Royal Bank of Canada first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.16M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Royal Bank of Canada held 722 shares of Structure Therapeutics worth $35K as of Q1 2026.
  • Royal Bank of Canada sold 9,478 Structure Therapeutics shares in Q1 2026, an estimated $649K.
  • Structure Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5656 holding.
  • Royal Bank of Canada first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Royal Bank of Canada's Structure Therapeutics position peaked at $5.16M in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.